Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
  • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Definitions

• sequence identity refers to identity between two sequences, usually amino acid sequences, which can be determined by sequence alignment programs like BLAST, PSI-BLAST
• SERF2 of the present invention may have further amino acids or protein components. It may be a fusion protein.
• extended SERF2 proteins may have in preferred embodiments a lim ⁇ ited size, e.g. up to 2000 amino acids, up to 1800 amino acids, up to 1600 amino acids, up to 1400 amino acids, up to 1200 amino acids, up to 1000 amino acids, up to 800 amino acids, up to 600 amino acids, up to 400 amino acids, up to 300 amino acids, up to 200 amino acids, or up to 160 amino acids.
• the inven ⁇ tion also relates to SERF2 proteins that consist of any one of said sequences comprised in the above mentioned embodiments.
• the atrophy treated according to the invention is associated with an increased apoptosis or reduced regenera ⁇ tion of cells.
• An atrophy might be a reduction of the mass of a certain tissue.
• a tissue can be a muscle (e.g. in sarcope- nia) , the skin (e.g. in medication- or age-caused skin thinning) , a bone or an internal organ such as the liver, a tissue of the hematopoietic system, e.g. bone marrow, spleen, tonsils, lymph nodes.
• the treated atrophy is a reduction of cells selected from the group of muscle cells, in particular heart muscle cells or skeletal muscle cells or smooth muscle cells, a connective tissue cell, in particular a cell of connec ⁇ tive tissue surrounding a muscle or a bone cell, epithelial cells, in particular blood vessel cells, and satellite cells, or bone cells (e.g. osteoblasts or osteoclasts).
• muscle cells in particular heart muscle cells or skeletal muscle cells or smooth muscle cells
• a connective tissue cell in particular a cell of connec ⁇ tive tissue surrounding a muscle or a bone cell
• epithelial cells in particular blood vessel cells, and satellite cells
• bone cells e.g. osteoblasts or osteoclasts
• SERF2 (as always including proteins, nucleic acids or cells) can be administered in any way known in the art.
• pre ⁇ ferred forms of administration are topical administrations.
• Pre ⁇ ferred topical administrations means are transdermal patches or by minipumps, which can continuously provide SERF2 on the site or tissue of need thereof.
• a systemic admin ⁇ istration is possible, to provide overall increased prolifera- tive activity.
• SERF2 can be linked, e.g.
• Fig. 2 Effect of SERF2 on Proliferation of rat skeletal muscle cells (L6) .
• lxlO 4 L6 cells were seeded per well containing ⁇ growth medium. Cells were incubated over night at +37°C, 5% v/v CO 2 and humidified atmosphere. Prior performing the assay, via ⁇ bility of cells was checked under the microscope. Cells were washed three times with ⁇ DPBS per well. SERF2 was diluted ⁇ g/ml) in DMEM and ⁇ /well were added to the cells. Finally, cells were incubated at +37°C for various time points. Subse ⁇ quently 10 ⁇ /well AlamarBlueTM reagent (Invitrogen) was added.
• Adherent cells are epidermoid carcinoma cells
• MCF-7 cells are epithelial cells
• ECV-304 was derived from a urinary bladder carcinoma .
• This operational window was fi ⁇ nally covered with sterile aluminium foil.
• Eggs were incubated at +37 °C, 5% v/v CO 2 and humidified atmosphere.
• E6 embryonic day 6
• a plastic foil (outer diameter 12mm, inner diameter of 3mm) was washed three times with 70% v/v ethanol and three times with sterile Locke (0,15M NaCl, 5mM KC1, 2mM CaC12, 2mM NaHCO 3 ) buffer.
• E6 embryonic day 6
• sterile Locke (0,15M NaCl, 5mM KC1, 2mM CaC12, 2mM NaHCO 3 ) buffer.
• the plastic foil was laid onto the CAM.
• Select ⁇ ed peptides were diluted and applied onto the CAM on E6 by pi ⁇ petting them in the middle of the plastic foil.
• Eggs were incu ⁇ bated at +37°C until E8 or Ell depending on type of experiment

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Epidemiology (AREA)
• Neurology (AREA)
• Zoology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Gastroenterology & Hepatology (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Immunology (AREA)
• Marine Sciences & Fisheries (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Physical Education & Sports Medicine (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Toxicology (AREA)
• Diabetes (AREA)
• Dermatology (AREA)
• Psychology (AREA)
• Hematology (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=47355920

Family Applications (1)

Country Status (7)

Cited By (9)

Families Citing this family (4)

Citations (1)

Family Cites Families (1)

• 2012
  • 2012-12-14 EP EP12197192.3A patent/EP2742935A1/en not_active Withdrawn
• 2013
  • 2013-12-13 EP EP13818997.2A patent/EP2931264A1/en not_active Withdrawn
  • 2013-12-13 CA CA2895131A patent/CA2895131A1/en not_active Abandoned
  • 2013-12-13 AU AU2013357283A patent/AU2013357283A1/en not_active Abandoned
  • 2013-12-13 WO PCT/EP2013/076547 patent/WO2014090991A1/en not_active Ceased
  • 2013-12-13 JP JP2015547046A patent/JP2016508123A/ja active Pending
  • 2013-12-13 US US14/651,809 patent/US9637529B2/en not_active Expired - Fee Related
  • 2013-12-13 CN CN201380072269.4A patent/CN105163726A/zh active Pending
• 2017
  • 2017-03-31 US US15/475,418 patent/US20170253641A1/en not_active Abandoned

Patent Citations (1)

Non-Patent Citations (4)

Also Published As

Similar Documents

Legal Events